Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Guanabenz in essential hypertension.

F G McMahon, J R Ryan, A K Jain

    Clinical Pharmacology and Therapeutics
    |March 1, 1977
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Profiling CARD14 gene expression in Indian Psoriasis patients.

    Scientific reports·2024
    Same author

    Exploring the diversity of virulence genes in the <i>Magnaporthe</i> population infecting millets and rice in India.

    Frontiers in plant science·2023
    Same author

    The Implementation of a Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) Program at a Level 1 New England Trauma Center: Feasibility and Early Outcomes.

    The American surgeon·2023
    Same author

    Added value of the measles-rubella supplementary immunization activity in reaching unvaccinated and under-vaccinated children, a cross-sectional study in five Indian districts, 2018-20.

    Vaccine·2022
    Same author

    Deep learning model for predicting tunnel damages and track serviceability under seismic environment.

    Modeling earth systems and environment·2022
    Same author

    Role of GeneXpertMTB/RIF in the diagnosis of cutaneous tuberculosis.

    The Indian journal of tuberculosis·2022
    Same journal

    Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug-Drug Interactions for Orforglipron, a Small Molecule Glucagon-Like Peptide-1 Receptor Agonist.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Resolving CYP2D6 Structural Complexity with Long-Read Sequencing: Implications for Tamoxifen Precision Dosing in Thai Breast Cancer Patients.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin-Angiotensin System Inhibitors.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Composite Endpoints in Contemporary Cardiovascular Trials: Trends in Phase 3 Trials and Key Issues in Regulatory Review.

    Clinical pharmacology and therapeutics·2026
    See all related articles

    Guanabenz effectively lowers blood pressure in patients with mild to moderate essential hypertension. This study found significant reductions in mean arterial pressure and diastolic blood pressure with minimal side effects.

    Area of Science:

    • Cardiovascular Medicine
    • Pharmacology

    Background:

    • Essential hypertension is a prevalent condition requiring effective treatment.
    • Guanabenz is an antihypertensive agent whose efficacy in mild to moderate essential hypertension warrants investigation.

    Purpose of the Study:

    • To evaluate the efficacy and safety of guanabenz in patients with mild to moderately severe essential hypertension.
    • To compare the effects of guanabenz with placebo in a randomized controlled trial.

    Main Methods:

    • A randomized, placebo-controlled study involving 55 patients with mild to moderately severe essential hypertension.
    • Patients received guanabenz (4-16 mg twice daily) or placebo, with crossover to guanabenz for placebo recipients.
    • Blood pressure (mean arterial and supine diastolic) and adverse effects were monitored.

    Related Experiment Videos

    Main Results:

    • Guanabenz significantly reduced mean arterial pressure (130.6 to 107.6) and supine diastolic blood pressure.
    • 84% of guanabenz-treated patients achieved a sustained decrease in supine diastolic blood pressure of ≥10 mm Hg, compared to 32% in the placebo group.
    • Common adverse effects included sedation, dry mouth, weakness, and tiredness, with no significant orthostatic hypotension observed.

    Conclusions:

    • Guanabenz demonstrates significant antihypertensive efficacy in patients with mild to moderately severe essential hypertension.
    • The drug is generally well-tolerated, with manageable side effects.
    • Guanabenz represents a viable therapeutic option for managing essential hypertension.